Personalized antisense oligonucleotide therapy for ATN1 mutation
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Personalized antisense oligonucleotide therapy for ATN1 mutation, covering 2026-04-09 to 2026-04-09. Get the full timeline:
Most recent: Clinical Trial Update: Personalized Antisense Oligonucleotide Therapy for A Single Participant With ATN1 Gene Mutation [Phase 1, Phase 2]